Acute Myocardial Infarction, Coronary Stent Thrombosis, Antithrombotic Therapy Clinical Trial
Residual thrombosis of stent struts may occur after the end of primary angioplasty and
determine distal embolization and further myocardial damage. Bivalirudin is considered the
most appropriate antithrombotic drug in the setting of primary PCI, but an initial increase
in stent thrombosis has been reported. In order to overcome this potential adverse event, a
prolonged infusion of bivalirudin after the end of PCI has been proposed.
This aim of this study is to test whether the use of long-term bivalirudin infusion, as
compared to the intra-procedural only administration, reduces residual thrombosis of stent
struts evaluated by optical coherence tomography (OCT) at the end of primary PCI and at 3-5
days follow-up.
A subgroup of patients enrolled in the MATRIX (Minimizing Adverse haemmhorragic events by
TRansradial access site and AngioX study) study will be selected showing the following
inclusion criteria:
- patients affected by STEMI undergoing primary PCI with stent implantation and
randomised to bivalirudin treatment,
- patients who, in addition to the infarct related lesion, show at least one critical
stenosis of other coronary vessels suitable for staged-PCI,
- patients whose anatomy is suitable for OCT evaluation.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment